Malignant tumor
Conditions
Interventions
experimental group:Fosapistan + Olanzapine + Palonosetron
control group:Fosapitan + Dexamethasone + Palonosetron
Sponsors
The First Affiliated Hospital of Xinxiang Medical College
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years(including boundary value), no gender restriction; 2. Subjects with solid malignancy confirmed by cytology or histology; 3. Comply with the NCCN guidelines and guidelines for vomiting prevention and treatment related to tumor treatment for hyperemetic chemotherapy; 4. Subjects undergoing primary chemotherapy for tumors; 5. Subject's physical status score (ECOG) 0-2 points (including boundary values); 6. Expected survival time >= 3 months; 7. Subjects can read, understand, and complete research questionnaires and diaries, including visual analog scale (VAS); 8. Subjects understood the study procedures and signed written informed consent.
Exclusion criteria
Exclusion criteria: 1. The subject has a mental disability or severe emotional or mental disorder, which the researcher considers unsuitable for inclusion in this study; 2. Except for malignant tumors, the subject has a history of active infections (such as pneumonia) or any uncontrolled disease (such as diabetic ketoacidosis, gastrointestinal obstruction), or any other disease history and the investigator believes may Interfering with research results or exposing subjects receiving study medication to unnecessary risks; 3. The subject has a digestive system disease that affects oral administration and absorption of the drug; 4. Subjects have concomitant diseases such as systemic fungal infections or uncontrolled diabetes that cannot be taken for 4 days; 5. Subjects should not receive any dose of systemic glucocorticoid therapy (except for the administration of the protocol) within 72 hours before starting antiemetic therapy, but local and inhaled glucocorticoids are allowed; 6. Patients known to be allergic to dexamethasone or olanzapine or other test medications.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete remission rate of vomiting;Control rate of vomiting;anxiety;Sleeping;Blood sugar; | — |
Countries
China
Contacts
Public ContactMin zhang
The First Affiliated Hospital of Xinxiang Medical College
Outcome results
None listed